{"generic":"Hepatitis B Immune Globulin","drugs":["Bayhep B","HepaGam B","Hepatitis B Immune Globulin","HyperHEP B","Nabi-HB","Nabi-HB NovaPlus"],"mono":{"0":{"id":"277200-s-0","title":"Generic Names","mono":"Hepatitis B Immune Globulin"},"1":{"id":"277200-s-1","title":"Dosing and Indications","sub":{"0":{"id":"277200-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HepaGam B(R) (blood exposure to HBsAg-positive source) 0.06 mL\/kg IM as a single dose as soon as possible and preferably within 7 days of exposure; give a second dose 1 month later to known non-responders to hepatitis B vaccine or in those who refuse vaccination<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HepaGam B(R) (sexual exposure to HBsAg-positive source) 0.06 mL\/kg IM as a single dose and initiate hepatitis B vaccine series within 14 days of sexual contact or if sexual contact will continue<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHep B(R), Nabi-HB(R) (unvaccinated persons with percutaneous or permucosal exposure to HBsAg-positive source) 0.06 mL\/kg IM as a single dose as soon as possible and within 24 hours of exposure if possible, and initiate hepatitis B vaccine series; OR if person refuses hepatitis B vaccine, 0.06 mL\/kg IM as a single dose as soon as possible and within 24 hours of exposure, and a second dose 1 month later<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHep B(R), Nabi-HB(R) (unvaccinated persons with percutaneous or permucosal exposure to known high-risk source) if source is found to be HBsAg-positive, 0.06 mL\/kg IM as a single dose as soon as possible and within 24 hours of exposure if possible, and initiate hepatitis B vaccine series; OR if person refuses hepatitis B vaccine, 0.06 mL\/kg IM as a single dose as soon as possible and within 24 hours of exposure, and a second dose 1 month later<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHep B(R), Nabi-HB(R) (vaccinated persons with percutaneous or permucosal exposure to HBsAg-positive source) if exposed person has an inadequate anti-hepatitis B antibody response, 0.06 mL\/kg IM as a single dose and booster hepatitis B vaccine as soon as possible and within 24 hours of exposure if possible; OR if person refuses hepatitis B vaccine, 0.06 mL\/kg IM as a single dose as soon as possible and within 24 hours of exposure, and a second dose 1 month later<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHep B(R), Nabi-HB(R) (vaccinated persons with percutaneous or permucosal exposure to known high-risk source) if exposed person is vaccine non-responder and source is found to be HBsAg-positive, 0.06 mL\/kg IM as a single dose and booster hepatitis B vaccine as soon as possible and within 24 hours of exposure if possible; OR if person refuses hepatitis B vaccine, 0.06 mL\/kg IM as a single dose as soon as possible and within 24 hours of exposure, and a second dose 1 month later<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHep B(R), Nabi-HB(R) (sexual exposure) 0.06 mL\/kg IM as a single dose within 14 days of the last sexual contact or if sexual contact with the infected person will continue; also begin the hepatitis B vaccine series at the same time the dose of hepatitis B immune globulin is given<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHep B(R), Nabi-HB(R) (contact with household member with acute hepatitis B virus infection and identifiable blood exposure such as sharing toothbrushes or razors) 0.06 mL\/kg IM as a single dose within 14 days of exposure or if exposure to the blood of the infected person will continue; also begin the hepatitis B vaccine series at the same time the dose of hepatitis B immune globulin is given; all household contacts should receive hepatitis B vaccine if the source patient becomes a hepatitis B virus carrier<\/li><li><b>Hepatitis B; Prophylaxis - Transplantation of liver:<\/b> HepaGam B(R), initial dose: 20,000 international units IV concurrent with grafting of the transplanted liver; week 1, postoperative dose: 20,000 international units IV once daily on days 1 to 7 postoperative; weeks 2 to 12, postoperative dose: 20,000 international units IV every 2 weeks starting on day 14; month 4 onward: 20,000 international units IV once a month; dosing is intended to attain serum levels of antibodies to hepatitis B surface antigen (anti-HBs) greater than 500 international units\/L<\/li><li><b>Hepatitis B; Prophylaxis - Transplantation of liver:<\/b> failure to reach anti-HBs levels of 500 international units\/L within first week posttransplantation, dosing regimen should be increased to a half-dose (10,000 international units) IV every 6 hours until the target anti-HBs is reached<\/li><\/ul>"},"1":{"id":"277200-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> household exposure in infants less than 12 months of age, acute hepatitis B infection in mother or primary caregiver: 0.5 mL IM as a single dose plus hepatitis B vaccine<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HepaGam B(R), Nabi-HB(R) (perinatal transmission prophylaxis in infants born to HBsAg-positive mothers) 0.5 mL IM within 12 hours of birth plus appropriate hepatitis B vaccine series; for infant born to mothers not screened for HBsAg, if mother is found to be HBsAg-positive, give 0.5 mL IM as soon as possible and within 1 week after birth plus appropriate hepatitis B vaccine series<\/li><li><b>Hepatitis B, Postexposure; Prophylaxis:<\/b> HyperHEP B(R) (perinatal transmission prophylaxis in infants born to HBeAg- or HBsAg-positive mothers) 0.5 mL IM within 12 hours of birth plus appropriate hepatitis B vaccine series; if hepatitis B vaccine is delayed for as long as 3 months, then give hepatitis B immune globulin and repeat at 3 months; if hepatitis B vaccine is refused, then give hepatitis B immune globulin and repeat at 3 and 6 months<\/li><\/ul>"},"3":{"id":"277200-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hepatitis B, Postexposure; Prophylaxis<\/li><li>Hepatitis B; Prophylaxis - Transplantation of liver<\/li><\/ul>"}}},"3":{"id":"277200-s-3","title":"Contraindications\/Warnings","sub":[{"id":"277200-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylactic or severe systematic reactions to parenteral human globulin<\/li><li>IgA deficiency; increased risk of anaphylactoid reaction<\/li><\/ul>"},{"id":"277200-s-3-10","title":"Precautions","mono":"<ul><li>hypersensitivity, severe, and anaphylactic reactions may occur; increased risk may occur in patients with IgA antibodies; discontinue with hypersensitivity reaction<\/li><li>thrombotic events may occur during or following therapy<\/li><li>advanced age; risk of thrombotic events<\/li><li>atherosclerosis or multiple cardiovascular risk factors; risk of thrombotic events<\/li><li>blood glucose monitoring; falsely elevated glucose levels in blood glucose monitoring based on glucose dehydrogenase pyrroloquinequinone (GDH-PQQ) method may occur with use of HepaGam B(TM)<\/li><li>cardiac output impaired; risk of thrombotic events<\/li><li>coagulation disorder; risk of bleeding due to intramuscular injection; risk of thrombotic events<\/li><li>human plasma derivative; infectious agent risk including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>hyperviscosity, known or suspected; risk of thrombotic events; baseline monitoring recommended<\/li><li>immobilization for prolonged periods; risk of thrombotic events<\/li><li>infusion reactions may occur; monitor for symptoms during and after infusion<\/li><li>report infections transmitted by HepaGam B(R) product to Cangene Corporation 1-800-768-2304 or caused by Nabi-HB(R) product to Nabi Biopharmaceuticals at 1-800-458-4244<\/li><li>thrombocytopenia, severe; risk of bleeding due to intramuscular injection<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"277200-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"277200-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"277200-s-4","title":"Drug Interactions","sub":{"2":{"id":"277200-s-4-15","title":"Moderate","mono":"<ul><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"277200-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (12%), Injection site pain (4%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (2% to 4%), Vomiting (2%)<\/li><li><b>Hematologic:<\/b>Decreased white blood cell count (Mild) (2%), Ecchymosis (Mild) (2%)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised (Mild) (4%), AST\/SGOT level raised (Mild) (2%)<\/li><li><b>Musculoskeletal:<\/b>Joint stiffness (Mild) (2%), Myalgia (10%)<\/li><li><b>Neurologic:<\/b>Headache (14%)<\/li><li><b>Renal:<\/b>Serum creatinine raised (Mild) (2%)<\/li><li><b>Other:<\/b>Malaise (6%)<\/li><\/ul>"},"6":{"id":"277200-s-6","title":"Drug Name Info","sub":{"0":{"id":"277200-s-6-17","title":"US Trade Names","mono":"<ul><li>Bayhep B<\/li><li>HyperHEP B<\/li><li>Nabi-HB<\/li><li>Nabi-HB NovaPlus<\/li><li>HepaGam B<\/li><\/ul>"},"2":{"id":"277200-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"277200-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"8":{"id":"277200-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"277200-s-8-24","title":"Distribution","mono":"Systemic: Vd: 15.3  plus or minus  6.2 L <br\/>"},"4":{"id":"277200-s-8-27","title":"Elimination Half Life","mono":"Systemic: 24.8  plus or minus  5.6 d <br\/>"}}},"9":{"id":"277200-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>HyperHep B(R) and Nabi-HB(R) products are for IM use only; do not give IV<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>preferred sites are the anterolateral aspect of upper thigh or the deltoid muscle of the upper arm<\/li><li>avoid injection into buttocks; if injection into the buttock is warranted due to volume to be injected, avoid central region and use upper outer quadrant, directing needle anteriorly to minimize sciatic nerve involvement<\/li><li>Nabi-HB(R), use within 6 hours after vial has been entered<\/li><li>concomitant use with hepatitic B vaccine, may give at the same time, but at a different site or up to 1 month preceding vaccination<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>volume of each dose is calculated from the measured potency of the particular lot of hepatitis B immune globulin IV stamped on the vial label<\/li><li>do not shake vial to avoid foaming; do not use if turbid<\/li><li>if dilution is preferred prior to IV administration, dilute with NS; do NOT use D5W<\/li><li>HepaGam B(R) is for single use only; discard unused portions<\/li><li>administer through a separate IV line using an infusion pump at a rate of 2 mL\/min; in case of discomfort or infusion-related adverse events, the rate of infusion should be decreased to 1 mL\/min or slower<\/li><\/ul><\/li><\/ul>"},"10":{"id":"277200-s-10","title":"Monitoring","mono":"<ul><li>liver transplantation: monitor serum anti-Hepatitis B surface antibody level regularly<\/li><li>liver transplantation: normal liver function tests may indicate efficacy<\/li><li>blood viscosity at baseline in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia\/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies<\/li><\/ul>"},"13":{"id":"277200-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid live vaccines other than hepatitis B vaccine for 3 months after receiving this drug.<\/li><li>Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional.<\/li><li>This drug may cause nausea, vomiting, ecchymosis, joint stiffness, myalgia, malaise, or headache.<\/li><li>Drug may cause thrombotic events. Patients at risk include those with advanced age, heart disease, coagulation disorders, hyperviscosity, prolonged periods of immobilization, and\/or hyperviscosity.<\/li><li>This product may interfere with some types of blood glucose monitoring systems, and can result in falsely elevated glucose readings. Instruct patients to use only testing systems that are glucose-specific.<\/li><\/ul>"}}}